Experience > Select Research Publications

Heinrich M, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors with Next-Generation Sequencing Results Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol. Published online February 09, 2017. doi:10.1001/jamaoncol.2016.6728. PMID: 28196207. https://www.ncbi.nlm.nih.gov/pubmed/?term=28196207

Valdivieso M, Bussalleu A, Sexton R, Thompson KC, Osorio S, Novoa Reyes, I, Crowley JJ, Baker LH, Xi C. Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru. Infection and Drug Resistance. 2017 March; 2017(10):85-90. PMID: 28331349. https://www.ncbi.nlm.nih.gov/pubmed/?term=28331349

Hoering A, Durie B, Wang H, Crowley J. End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.Future Oncol. 2017 Apr 11.

Matsui S, Noma H, Qu P, Sakai Y, Matsui K, Heuck C, Crowley J. Multi-subgroup gene screening using semi-parametric hierarchical mixture models and the optimal discovery procedure: Application to a randomized clinical trial in multiple myeloma.Biometrics. 2017 May 12.

Chansky K, Detterbeck FC, Andrew G Nicholson AG, Valerie Rusch W, Vallières E, Groome P, Kennedy C, Krasnik M, Peak M, Shemanski L, Bolejack V, Crowley JJ, Asamura H, Rami-Porta R. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology. In press. PMID: 28461257. https://www.ncbi.nlm.nih.gov/pubmed/28461257

Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2016 Dec 22. pii: S0140-6736(16)31594-X. PMID: 28017406. https://www.ncbi.nlm.nih.gov/pubmed/?term=28017406

Jethava Y, Mitchell A, Epstein J, Zangari M, Yaccoby S, Tian E, Waheed S, Khan R, Papanikolaou X, Grazziutti M, Cottler-Fox M, Petty N, Steward D, Panozzo S, Bailey C, Hoering A, Crowley J, Sawyer J, Morgan G, Barlogie B, van Rhee F. Adverse metaphase cytogenetics can be overcome by adding bortezomib and thalidomide to fractionated melphalan transplants. Clin Cancer Res. 2016 Nov 3. pii: clincanres.2620.2015. PMID: 27810902. https://www.ncbi.nlm.nih.gov/pubmed/?term=27810902

Pedersen EA, Menon R, Bailey KM, Thomas DG, Van Noord RA, Tran J, Wang H, Qu P, Hoering A, Fearon ER, Chugh R, Lawlor ER. Activation of Wnt/beta-catenin in Ewing sarcoma cells antagonizes EWS/ETS function and promotes phenotypic transition to more metastatic cell states. Cancer Res. 2016 Jun 30. pii: canres.3422.2015. [Epub ahead of print] PMID: 27364557. https://www.ncbi.nlm.nih.gov/pubmed/?term=27364557

Pedersen EA, Menon R, Bailey KM, Thomas DG, Van Noord RA, Tran J, Wang H, Qu PP, Hoering A, Fearon ER, Chugh R, Lawlor ER (2016 Sept 1). Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States. Cancer Res. 76(17):5040-53. doi: 10.1158/0008-5472.CAN-15-3422. Epub 2016 Jun 30. PMID: 27364557. https://www.ncbi.nlm.nih.gov/pubmed/?term=27364557

Schinke C, Hoering A, Hongwei W, Carlton V, Thanandrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo kamimoto J, Grazziutti M, van Rhee F, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ (2016). The Prognostic Value of the Depth of Response in Multiple Myeloma Depends on the Time of Assessment, Risk Status and Molecular Subtype. Submitted to Haematologica – under revision.

Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, Eberhardt WE, van Meerbeeck J, Rami-Porta R; Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016 Mar; 11 (3):300-11. doi: 10.1016/j.jtho.2015.10.008. Epub 2015 Dec 24. PMID: 26723244. https://www.ncbi.nlm.nih.gov/pubmed/?term=26723244

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016 Jan; 11 (1):39-51. doi: 10.1016/j.jtho.2015.09.009. PMID: 26762738. https://www.ncbi.nlm.nih.gov/pubmed/?term=26762738

Crowley JJ. IBS Past Presidents: Norman Breslow. Biometric Bulletin. 2016 Jan-Mar; 33(1).

Goodman PJ, Tangen CM, Darke AK, Arnold KB, Hartline J, Yee M, Anderson K, Caban-Holt A, Christen WG, Cassano PA, Lance P, Klein EA, Crowley JJ, Minasian LM, Meyskens FL. Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial. Trials. 2016 Aug 12; 17:400. doi: 10.1186/s13063-016-1524-9. PMID: 27519183; PMCID: PMC4983010. https://www.ncbi.nlm.nih.gov/pubmed/?term=27519183

Valdivieso M, Bussalleu A, Sexton R, Boehnke K, Osorio S, Novoa Reyes I, Crowley JJ, Goodman GE, Baker LH, Xi C. Clinical, Epidemiologic, and Genomic Studies (SWOG S1119) of Helicobacter Pylori in Lima, Peru: Role of Contaminated Water. J Cancerol. 2016; 2:52-63

Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA. PD-1 Blockade with Pembrolizumab in Advances Merkel-Cell Carcinoma. N Engl J Med. 2016 Apr 19; DOI: 10.1056/NEJMoa1603702. PMID: 27093365. https://www.ncbi.nlm.nih.gov/pubmed/27093365

Detterbeck FC, Chansky K, Groome P, Bolejack V, Crowley J, Shemanski L, Kennedy C, Krasnik M, Peake M, Rami-Porta R; IASLC Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions. The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2016 Sep;11 (9):1433-46. PMID: 27448762. https://www.ncbi.nlm.nih.gov/pubmed/27448762

Fredlund P, Hillson J, Gray T, Shemanski L, Dimitrova D, Srinivasan S. Peginterferon Lambda-1a Is Associated with a Low Incidence of Autoimmune Thyroid Disease in Chronic Hepatitis C. J Interferon Cytokine Res. 2015 Nov;35(11):841-3. doi: 10.1089/jir.2014.0233. PMID: 26376344. https://www.ncbi.nlm.nih.gov/pubmed/26376344

Rice D, Chansky K, Nowak A, Pass H, Kindler H, Shemanski L, Opitz I, Call S, Hasegawa S, Kernstine K, Atinkaya C, Rea F, Nafteux P, Rusch VW; Mesothelioma Domain of the IASLC Staging and Prognostic Factors Committee, advisory boards and participating institutions. J Thorac Oncol. 2016 Dec;11 (12):2100-2111. doi: 10.1016/j.jtho.2016.09.121.

Nowak AK, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, Billé A, Rintoul RC, Batirel HF, Thomas CF, Friedberg J, Cedres S, de Perrot M, Rusch VW; Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. J Thorac Oncol. 2016 Dec;11(12):2089-2099. doi: 10.1016/j.jtho.2016.08.147. PMID: 27687963. https://www.ncbi.nlm.nih.gov/pubmed/27687963

Rusch VW, Chansky K, Kindler HL, Nowak AK, Pass HI, Rice DC, Shemanski L, Galateau-Sallé F, McCaughan BC, Nakano T, Ruffini E, van Meerbeeck JP, Yoshimura M; IASLC Staging and Prognostic Factors Committee, advisory boards, and participating institutions. J Thorac Oncol. 2016 Dec;11(12):2112-2119. doi: 10.1016/j.jtho.2016.09.124. PMID: 27687962. https://www.ncbi.nlm.nih.gov/pubmed/?term=27687962

Tosteson AN, Beaber EF, Tiro J, Kim J, McCarthy AM, Quinn VP, Doria-Rose VP, Wheeler CM, Barlow WE, Bronson M, Garcia M, Corley DA, Haas JS, Halm EA, Kamineni A, Rutter CM, Tosteson TD, Trentham-Dietz A, Weaver DL; PROSPR consortium. Variation in screening abnormality rates and follow-up of breast, cervical and colorectal cancer screening within the PROSPR Consortium. J Gen Intern Med. 2016; 31:372-9. PMID: 26658934; PMCID: PMC4803707. https://www.ncbi.nlm.nih.gov/pubmed/?term=26658934

Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, Barlow WE, Blanke C, Thompson IM, Hussain M. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2016; 2:453-61. PMID: 26720308. PMCID: PMC4852142. https://www.ncbi.nlm.nih.gov/pubmed/?term=26720308

McCarthy AM, Kim JJ, Beaber EF, Zheng Y, Burnett-Hartman A, Chubak J, Ghai NR, McLerran D, Breen N, Conant EF, Geller BM, Green BB, Klabunde CN, Inrig S, Skinner CS, Quinn VP, Haas JS, Schnall M, Rutter CM, Barlow WE, Corley DA, Armstrong K, Doubeni CA; PROSPR consortium. Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity. Am J Prev Med. 2016; 51:507-12. PMID: 27132628; PMCID: PMC5030116. https://www.ncbi.nlm.nih.gov/pubmed/?term=27132628

Unger JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL. The scientific impact of positive and negative Phase 3 cancer clinical trials. JAMA Oncol. 2016; 2:875-81. PMID: 26967260; PMCID: PMC4945370. https://www.ncbi.nlm.nih.gov/pubmed/?term=26967260

Conant EF, Beaber EF, Sprague BL, Herschorn SD, Weaver DL, Onega T, Tosteson AN, McCarthy AM, Poplack SP, Haas JS, Armstrong K, Schnall MD, Barlow WE. Breast cancer screening using tomosynthesis in combination with digital mammography compared to digital mammography alone: a cohort study within the PROSPR consortium. Breast Cancer Res Treat. 2016; 156:109-16. PMID: 26931450. https://www.ncbi.nlm.nih.gov/pubmed/?term=26931450

Hertz DL, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF, Hortobagyi GN, Mehta RS, Rae JM. Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. Br J Clin Pharmacol. 2016; 81:1134-41. PMID: 26859101. https://www.ncbi.nlm.nih.gov/pubmed/?term=26859101

Unger JM, Till C, Thompson IM Jr, Tangen CM, Goodman PJ, Wright JD, Barlow WE, Ramsey SD, Minasian LM, Hershman DL. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. JNCI. 2016; 108(12). PMID: 27565902. https://www.ncbi.nlm.nih.gov/pubmed/?term=27565902

Schott AF, Barlow WE, Van Poznak CH, Hayes DF, Moinpour CM, Lew DL, Dy PA, Keller ET, Keller JM, Hortobagyi GN. Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat. 2016; 159:87-95. PMID: 27475087; PMCID: PMC5021222. https://www.ncbi.nlm.nih.gov/pubmed/?term=27475087

Sprague BL, Conant EF, Onega T, Garcia MP, Beaber EF, Herschorn SD, Lehman CD, Tosteson AN, Lacson R, Schnall MD, Kontos D, Haas JS, Weaver DL, Barlow WE; PROSPR Consortium. Variation in Mammographic Breast Density Assessments Among Radiologists in Clinical Practice: A Multicenter Observational Study. Ann Intern Med. 2016; 165:457-464. PMID: 27428568; PMCID: PMC5050130. https://www.ncbi.nlm.nih.gov/pubmed/?term=27428568

Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat. 2016; 158:485-95. PMID: 27393622; PMCID: PMC4963434. https://www.ncbi.nlm.nih.gov/pubmed/?term=27393622

Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, Minasian LM, Unger J. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol. 2016; 34:3014-22. PMID: 27325863; PMCID: PMC5012713. https://www.ncbi.nlm.nih.gov/pubmed/?term=27325863

Beaber EF, Tosteson AN, Haas JS, Onega T, Sprague BL, Weaver DL, McCarthy AM, Doubeni CA, Quinn VP, Skinner CS, Zauber AG, Barlow WE. Breast cancer screening initiation after turning 40 years of age within the PROSPR consortium. Breast Cancer Res Treat. 2016; 160:323-331. PMID: 27665586. https://www.ncbi.nlm.nih.gov/pubmed/?term=27665586

Unger JM, Barlow WE, Hershman DL. Measuring the real clinical impact of randomized clinical trials in oncology-Reply: Beyond citation counts. JAMA Oncol. 2016; 2:1511. PMID: 27355398. https://www.ncbi.nlm.nih.gov/pubmed/?term=27355398

Pedersen EA, Menon R, Bailey KM, Thomas DG, Van Noord RA, Tran J, Wang H, Qu PP, Hoering A, Fearon ER, Chugh R, Lawlor ER. Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States. Cancer Res. 2016 Sep 1;76(17):5040-53. doi: 10.1158/0008-5472.CAN-15-3422. Epub 2016 Jun 30. PMID: 27364557. https://www.ncbi.nlm.nih.gov/pubmed/?term=27364557

Nicholson AG, Groome P, Mitchell A, Bolejack V. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11:39-51. PMID: 26762738. https://www.ncbi.nlm.nih.gov/pubmed/?term=26762738

Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, Eberhardt WE, van Meerbeeck J, Rami-Porta R. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11:300-11.

Detterbeck FC, Nicholson AG, Franklin WA, Marom EM, Travis WD, Girard N, Arenberg DA, Bolejack V, Donington JS, Mazzone PJ, Tanoue LT, Rusch VW, Crowley J, Asamura H, Rami-Porta R. The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. J Thorac Oncol. 2016; 11:639-50. PMID: 26940528. https://www.ncbi.nlm.nih.gov/pubmed/?term=26940528

Detterbeck FC, Nicholson AG, Franklin WA, Marom EM, Travis WD, Girard N, Arenberg DA, Bolejack V, Donington JS, Mazzone PJ, Tanoue LT, Rusch VW, Crowley J, Asamura H, Rami-Porta R. The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. J Thorac Oncol. 2016; 11:639-50. PMID: 26940528. https://www.ncbi.nlm.nih.gov/pubmed/?term=26940528

Detterbeck FC, Bolejack V, Arenberg DA, Crowley J, Donington JS, Franklin WA, Girard N, Marom EM, Mazzone PJ, Nicholson AG, Rusch VW, Tanoue LT, Travis WD, Asamura H, and Rami-Porta R. The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11:681-92. PMID:26944304. https://www.ncbi.nlm.nih.gov/pubmed/26944304

Nowak AK, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, Billé A, Rintoul RC, Batirel HF, Thomas CF, Friedberg J, Cedres S, de Perrot M, and Rusch VW. The IASLC mesothelioma staging project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol. 2016;11:2089–2099. PMID: 27687963. https://www.ncbi.nlm.nih.gov/pubmed/27687963

Rice D, Chansky K, Nowak A, Pass H, Kindler H, Shemanski L, Opitz I, Call S, Hasegawa S, Kernstine K, Atinkaya C, Rea F, Nafteux P, and Rusch VW. The IASLC mesothelioma staging project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol. 2016;11:2100–2111. PMID: 27687964. https://www.ncbi.nlm.nih.gov/pubmed/27687964

Andreotti G, Katz M, Hoering A, Van Ness B, Crowley J, Morgan G, Hoover RN, Baris D, Durie B. Risk of multiple myeloma in a case-spouse study. Leuk Lymphoma. 2015 Nov 16:1-10. PMID: 26422532. https://www.ncbi.nlm.nih.gov/pubmed/?term=26422532

Stein CK, Qu P, Epstein J, Buros A, Rosenthal A, Crowley J, Morgan G, Barlogie B. Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat. BMC Bioinformatics. 2015 Feb 25;16:63. doi: 10.1186/s12859-015-0478-3. PMID: 25887219; PMCID: PMC4355992. https://www.ncbi.nlm.nih.gov/pubmed/?term=25887219

Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J, Yaccoby S, Hoering A, Crowley J, Petty N, Bailey C, Morgan G, Barlogie B. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica. 2015 May 28. pii: haematol.2015.124651. [Epub ahead of print] PMID: 26022710. https://www.ncbi.nlm.nih.gov/pubmed/?term=26022710

Qu P, Barlogie B, Crowley J. Using a latent class model to refine risk stratification in multiple myeloma. Stat Med. 2015 Sep 20;34(21):2971-80. doi: 10.1002/sim.6557. Epub 2015 Jun 17. PMID: 26084662. https://www.ncbi.nlm.nih.gov/pubmed/?term=26084662

Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J, Yaccoby S, Hoering A, Crowley J, Petty N, Bailey C, Morgan G, and Barlogie B (2015). Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica, 100(9): 1214-21, doi: 10.3324/haematol. 2015.124651. PMID: 26022710. https://www.ncbi.nlm.nih.gov/pubmed/26022710

Qu P, Barlogie B, Crowley J. Using a latent class model to refine risk stratification in multiple myeloma. Stat Med. 2015 Sep 20; 34 (21):2971-80. doi: 10.1002/sim.6557. Epub 2015 Jun 17. PMID: 26084662. https://www.ncbi.nlm.nih.gov/pubmed/?term=26084662

Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, Rice T, Suzuki K, Thomas CF Jr, Travis WD, Wu YL; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015 Jul; 10(7):990-1003. doi: 10.1097/JTO.0000000000000559. PMID: 26134221. https://www.ncbi.nlm.nih.gov/pubmed/?term=26134221

Dhodapkar MV, Sexton R, Das R, Dhodapkar KM, Zhang L, Sundaram R, Soni S, Crowley JJ, Orlowski RZ, Barlogie B. Prospective analysis of antigen-specific immunity, stem cell antigens and immune checkpoints in monoclonal gammopathy. Blood. 2015 Oct 14. pii: blood-2015-03-632919. [Epub ahead of print] PMID: 26468228. https://www.ncbi.nlm.nih.gov/pubmed/?term=26468228

Eberhardt W, Mitchell A, Crowley JJ, Kondo H, Kim Y, Turrisi A, Goldstraw P, Rami-Porta R; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2015 Nov; 10(11):1515-1522. PMID: 26536193. https://www.ncbi.nlm.nih.gov/pubmed/?term=26536193

Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, Watanabe H, Wu YL, Zielinski M, Ball D, Rami-Porta R; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015 Dec; 10 (12):1675-84. doi: 10.1097/JTO.0000000000000678. PMID: 26709477. https://www.ncbi.nlm.nih.gov/pubmed/?term=26709477

Ramsey SD, Henry NL, Gralow JR, Mirick DK, Barlow W, Etzioni R, Mummy D, Thariani R, Veenstra DL. Tumor Marker Usage and Medical Care Costs Among Older Early-Stage Breast Cancer Survivors. J Clin Oncol. 2015 Jan 10;33(2):149-55. doi: 10.1200/JCO.2014.55.5409. Epub 2014 Oct 20. PMID: 25332254; PMCID: PMC4279234. https://www.ncbi.nlm.nih.gov/pubmed/?term=25332254

Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 Mar 5;372(10):923-32. doi: 10.1056/NEJMoa1413204. PMID: 25738668; PMCID: PMC4405231. https://www.ncbi.nlm.nih.gov/pubmed/?term=25738668

Tilan JU, Krailo M, Barkauskas DA, Galli S, Mtaweh H, Long J, Wang H, Hawkins K, Lu C, Jeha D, Izycka-Swieszewska E, Lawlor ER, Toretsky JA, Kitlinska JB. --- Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival. --- Cancer. 2015 Mar 1;121(5):697-707. doi: 10.1002/cncr.29090. Epub 2014 Nov 11. PMID: 25387699. https://www.ncbi.nlm.nih.gov/pubmed/25387699

Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, Rice T, Suzuki K, Thomas CF Jr, Travis WD, Wu YL. Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015;10:990-1003. PMID: 26134221. https://www.ncbi.nlm.nih.gov/pubmed/?term=26134221

Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, Watanabe H, Wu YL, Zielinski M, Ball D, Rami-Porta R. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer.. J Thorac Oncol. 2015; 10:1675-1684. PMID: 26709477. https://www.ncbi.nlm.nih.gov/pubmed/?term=26709477

Eberhardt WE, Mitchell A, Crowley J, Kondo H, Kim YT, Turrisi A 3rd, Goldstraw P, Rami-Porta R. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer.. J Thorac Oncol. 2015;10:1515–22. PMID: 26536193. https://www.ncbi.nlm.nih.gov/pubmed/?term=26536193

Crowley J, Qu P and Barlogie B (2014). Ethical issues in getting it right: using big data to determine medical treatment. In JSM Proceedings, Committee on professional ethics. Alexandria, VA: American Statistical Association. 56-67.

Heuck CJ, Qu P, van Rhee F, Waheed S, Usmani SZ, Epstein J, Zhang Q, Edmondson R, Hoering A, Crowley J and Barlogie B (2014). Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma. Leukemia, 28(12): 2410-3. doi: 10.1038/leu.2014.232. PMID: 25079174. https://www.ncbi.nlm.nih.gov/pubmed/?term=25079174

Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, LeBlanc M, Ramsey SR. The diffusion of docetaxel in patients with metastatic prostate cancer. J Natl Cancer Inst. 2014 Dec 24;107(2). pii: dju412. doi: 10.1093/jnci/dju412. Print 2015 Feb. PMID: 25540245; PMCID: PMC4326312. https://www.ncbi.nlm.nih.gov/pubmed/?term=25540245

Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H, and Goldstraw P. The IASLC Lung Cancer Staging Project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2014; 9:1618–1624. PMID: 25436796. https://www.ncbi.nlm.nih.gov/pubmed/25436796

Pass HI, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP, and Rusch VW. Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee. J Thorac Oncol. 2014; 9:856–864. PMID: 24807157. https://www.ncbi.nlm.nih.gov/pubmed/?term=24807157

Nicholson A, Detterbeck FC, Marino M, Kim J, Stratton K, Giroux D, Asamura H, John Crowley J, Falkson C, PL, Giaccone G, Huang J, Kondo K, Lucchi M, Marom E, Okumura M, Ruffini E, and Van Schil P. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the T component for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. J Thor Oncol 2014;9:S73–S80.

Kondo K, Van Schil P, Detterbeck FC, Okumura M, Stratton K, Giroux D, Asamura H, John Crowley J, Falkson C, PL, Giaccone G, Huang J, Kim J, Lucchi M, Marino M, Marom E, Nicholson AG, and Ruffini E. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the N and M Components for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. J Thor Oncol 2014;9 S81–S87. PMID: 25396316. https://www.ncbi.nlm.nih.gov/pubmed/?term=25396316

Usmani SZ, Hoering A. Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal. Leukemia. 2013 Dec;27(12):2269-71. PMID: 24326595. https://www.ncbi.nlm.nih.gov/pubmed/?term=24326595

Hoering A, Mitchell A, LeBlanc M, Crowley J. Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents. Clin Trials. 2013;10(3):422-9. PMID: 23529697; PMCID: PMC3744092. https://www.ncbi.nlm.nih.gov/pubmed/?term=23529697

Unger JM, Hershman DL, Albain KS, Moinpour CM, Petersen JA, Burg K, Crowley JJ. Patient income level and cancer clinical trial participation. J Clin Oncol. 2013 Feb 10;31(5):536-42. doi: 10.1200/JCO.2012.45.4553. PMID: 23295802; PMCID: PMC3565180. https://www.ncbi.nlm.nih.gov/pubmed/?term=23295802

Kryscio RJ, Abner EL, Schmitt FA, Goodman PJ, Mendiondo M, Caban-Holt A, Dennis BC, Mathews M, Klein EA, Crowley JJ. A Randomized Controlled Alzheimer's Disease Prevention Trial's Evolution into an Exposure Trial: The PREADViSE Trial. J Nutr Health Aging. 2013;17(1):72-5. doi: 10.1007/s12603-012-0083-3. PMID: 23299383. https://www.ncbi.nlm.nih.gov/pubmed/?term=23299383%5D

Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013 Mar 7;121(10):1819-23. doi: 10.1182/blood-2012-08-451690. PMID: 23305732; PMCID: PMC3591801. https://www.ncbi.nlm.nih.gov/pubmed/?term=23305732

Detterbeck F, Asamura H, Crowley J, Falkson C, PL, Giaccone G, Giroux D, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom E, Nicholson AG, Okumura M, Ruffini E, Van Schil P, and Stratton K. The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies. J Thorac Oncol 2013;8:1467–1473. PMID: 24389429. https://www.ncbi.nlm.nih.gov/pubmed/24389429

Chien JW, Zhang XC, Fan W, Wang H, Zhao LP, Martin PJ, Storer BE, Boeckh M, Warren EH, Hansen JA. Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood. 2012 May 31;119(22):5311-9. PMID: 22282500; PMCID: PMC3369619. https://www.ncbi.nlm.nih.gov/pubmed/?term=22282500

Goodman, K., Krueger, J., & Crowley, J. (2012). The automatic clinical trial: Leveraging the electronic medical record in multisite cancer clinical trials. Current Oncology Reports, 14(6), 509-518, doi: 10.1007/s11912-012-0262-8. PubMed: PMCID: PMC3490046. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490046/

Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Pass H, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, and van Meerbeeck JP. Initial analysis of the International Association for the Study of Lung Cancer mesothelioma database. J Thorac Oncol. 2012;7: 1631–1639. PMID: 23070243. https://www.ncbi.nlm.nih.gov/pubmed/23070243

Rusch VW, Giroux D. Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database. Ann Cardiothorac Surg. 2012;1:438-48. PMID: 23977534. https://www.ncbi.nlm.nih.gov/pubmed/?term=PMC3741785

  • Handbook of Statistics in Clinical Oncology, Third Edition
  • Edited by John Crowley, Ph.D. and Antje Hoering, Ph.D.
  • Published by Taylor & Francis Group, 2012.
  • Available now at Amazon.com

According to the publisher, the Handbook Second Edition "is the best single source for up-to-date statistical approaches to research in clinical medicine."

More than just an update of the handbook that became the gold standard, this third edition brings you fully into the genomic era of medicine.

  • Clinical Trials in Oncology, Third Edition
  • by Stephanie Green, Ph.D., Jacqueline Benedetti, Ph.D., Angela Smith and John Crowley, Ph.D.
  • Published by Taylor & Francis Group, 2012
  • Available now at Amazon.com

Clinical Trials in Oncology emphasizes the importance of proper study, design and data management, and explains why communication and partnership between statisticians and clinicians are vital to the conduct of a successful trial.

Clinical Trials in Oncology is written for research oncologists and graduate students in biostatistics. It also provides essential information for statisticians involved with cancer clinical trials.